A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis

Inclusion Criteria: Part 1 (healthy male subjects) * Healthy male subjects, 18 to 50 years of age (inclusive), and in good health as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and laboratory tests at screening * Body mass index (BMI) above or equal to 18.5 and lower or equal to 30 kg/m2 (BMI = body weight (kg) / \[height (m)\]2 and a body weight above or equal 50 kg Part 2 (patients with psoriasis) * Male patients, 18 to 70 years of age (inclusive) or female patients of non-child bearing potential, 30 to 70 years of age (inclusive) * Body mass index above or equal to 18.5 and lower or equal to 35 kg/m\*2 and a body weight above 50 kg * A documented diagnosis of psoriasis, with a history of at least 6 months prior to study drug administration. Moderate to severe plaque psoriasis at screening, defined by: a) an involved body surface area (BSA) above or equal to 10% of BSA, b) a Psoriasis Area and Severity Index (PASI) score of above or equal, 12 c) a Physician's Global Assessment (PGA) score of above or equal 2. Exclusion Criteria: * History of hypersensitivity to any of the components of the study drug * Any clinically relevant abnormal findings in safety laboratory parameters and ECG * History of tuberculosis (TB) or active or latent tuberculosis * Receipt of live or attenuated vaccine 90 days prior to the first dosing